Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Middle East Conflict Impacts Australia and New Zealand Businesses 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
LAKE FOREST, Ill., May 03, 2018 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first-quarter 2018 financial results on Thursday, May 10, 2018, before the open of markets. Following the announcement, the Company will host a conference call beginning at 8:30 a.m. ET to discuss its results.
Participants can access the live webcast from the Investor Relations section of Depomed's website at http://www.depomed.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
Audio Conference Call:
| U.S. Dial-in Number: | 1-877-326-2337 |
| International Dial-in Number: | 1-631-456-4258 |
| Conference ID: | 1328285277 |
An archived webcast replay will be available on the Company's website for three months.
About Depomed
Depomed is a leading specialty pharmaceutical company committed to putting the patient first in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain businesses and its emerging Orphan Specialty Business is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACTS:
John B. Thomas
SVP, Investor Relations and Corporate Communications
[email protected]
